Clinical Trials Sponsored by Allogene Therapeutics

Total 6330 results

Adiso Therapeutics

Completed

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

Clostridium Difficile Infection Recurrence

United States, Canada
ONL Therapeutics

Completed

A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment

Rhegmatogenous Retinal Detachment - Macula Off

Australia
Akebia Therapeutics

Completed

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (FO2RWARD-2)

Anemia | Dialysis-dependent Chronic Kidney Disease

United States
United Therapeutics

Completed

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
Amnis Therapeutics

Terminated

Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study

Ischemic Stroke

Spain, Sweden
Elevar Therapeutics

Completed

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (ANGEL)

Gastric Cancer | Gastric Adenocarcinoma

United States, United Kingdom, Korea, Republic of, France, Taiwan, Japan, Russian Federation, Germany, Italy, Poland, Romania, Ukraine
Sage Therapeutics

Completed

Evaluate SAGE-547 in Participants With Essential Tremor

Essential Tremor

United States
Nektar Therapeutics

Terminated

A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)

Melanoma | Sarcoma | Renal Cell Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Merkel Cell Carcinoma

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
PTC Therapeutics

Terminated

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Limb-Girdle Muscular Dystrophy

United States, Norway, Canada, Sweden, Russian Federation, Denmark, France, Germany
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Aprea Therapeutics

Completed

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Gastric Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma

United States
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA)

Eye Diseases | Retinitis | Eye Diseases, Hereditary | Retinal Dystrophies | Vision Disorders | Retinal Disease | Autosomal Dominant Retinitis Pigmentosa | Vision Tunnel

United States
Sage Therapeutics

Completed

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus (SRSE)

Super-refractory Status Epilepticus

United States
Amicus Therapeutics

Terminated

Natural History Study of Batten Disease

Batten Disease | Neuronal Ceroid Lipofuscinosis CLN6 | Neuronal Ceroid Lipofuscinosis CLN3

United States
Intrinsic Therapeutics

Completed

Barricaid EU Post Market Study for Primary Lumbar Disc Herniation

Lumbar Disc Herniation
PTC Therapeutics

Completed

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren

Duchenne Muscular Dystrophy

United States
Sangamo Therapeutics

Terminated

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Hemophilia B

United States
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
Aligos Therapeutics

Terminated

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Chronic Hepatitis B

Korea, Republic of, China, Hong Kong, United Kingdom, New Zealand, Moldova, Republic of
Cartesian Therapeutics

Completed

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Multiple Myeloma

United States
Allarity Therapeutics

Completed

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (LiPlaCis)

Phase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Denmark
Heron Therapeutics

Completed

Dose-Escalation Study of HTX-034 Following Bunionectomy

Bunions

United States
Sage Therapeutics

Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Healthy Volunteer

United States
Sage Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Huntington Disease

United States
Sage Therapeutics

Completed

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Postpartum Depression

United States
Sage Therapeutics

Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
Sage Therapeutics

Completed

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

Postpartum Depression

United States
Amicus Therapeutics

Completed

Gene Therapy for Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease

Variant Late-Infantile Neuronal Ceroid Lipofuscinosis

United States
Celldex Therapeutics

Completed

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Healthy Subjects

United States
Sage Therapeutics

Completed

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Healthy Volunteer

United States
Halozyme Therapeutics

Completed

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Dermatitis, Allergic Contact

United States
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
Fate Therapeutics

Terminated

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Hematologic Malignancies

United States
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Blade Therapeutics

Completed

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

Relative Bioavailability

Australia
Heron Therapeutics

Completed

Phase 2B Upper Extremity Nerve Block Study

Postoperative Pain

United States
Halozyme Therapeutics

Completed

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Bladder Cancer

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

Wounds

United States
Heron Therapeutics

Completed

Bunionectomy Study for Postoperative Analgesia (EPOCH 1)

Postoperative Pain

United States
Heron Therapeutics

Completed

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Postoperative Pain

United States, Belgium
Heron Therapeutics

Completed

Phase 2 Herniorrhaphy Study for Opioid Elimination

Postoperative Pain

United States
Causeway Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

Tennis Elbow

United Kingdom
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
UNION therapeutics

Completed

Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers

Covid19

Denmark
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Cadent Therapeutics

Completed

A Clinical Study to Evaluate CAD-1883 in Essential Tremor

Essential Tremor

United States
Nektar Therapeutics

Completed

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Colorectal Cancer

United States, Belgium, Germany, India, Spain, United Kingdom

Clinical Trials Sponsored by Allogene Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations